Disseminated Intravascular Coagulation: ISTH Score, Management, and Component Therapy
Acquired consumptive coagulopathy — pathogenesis, ISTH overt DIC scoring, treatment of underlying cause, and component replacement therapy
Executive Summary
Disseminated intravascular coagulation (DIC) is an acquired syndrome of widespread intravascular activation of coagulation, leading to simultaneous microvascular thrombosis and consumption of platelets and clotting factors that produces both organ ischemia and bleeding. DIC is always secondary to an underlying disorder—sepsis (most common, 30-50%), malignancy (especially adenocarcinoma and acute promyelocytic leukemia), trauma, obstetric catastrophes (placental abruption, amniotic fluid embolism, severe preeclampsia/HELLP), severe pancreatitis, snake envenomation, and transfusion reactions. The ISTH overt DIC scoring system uses platelet count, elevated fibrin marker (D-dimer or FDP), prolonged PT, and fibrinogen to confirm overt DIC at score ≥5 with sensitivity 91% and specificity 97%. Two distinct phenotypes guide management: hemorrhagic DIC (sepsis, obstetric, trauma) features platelet consumption, factor depletion, and bleeding diathesis; thrombotic DIC (chronic malignancy, large-vessel thrombosis, purpura fulminans) features fibrin deposition with end-organ ischemia. The cornerstone of treatment is aggressive management of the underlying cause—antibiotics for sepsis, delivery for obstetric DIC, leukapheresis and ATRA for APL. Component therapy is reserved for active bleeding or planned invasive procedures: platelets if <50,000/µL with bleeding (or <20,000/µL without), fresh frozen plasma 10–15 mL/kg IV if INR >1.5 with bleeding, cryoprecipitate 1 unit per 5–10 kg IV if fibrinogen <150 mg/dL (or <200 mg/dL in obstetric DIC). Anticoagulation is reserved for thrombotic-phenotype DIC. Mortality ranges from 30-60% depending on underlying cause and severity; ISTH score ≥5 doubles mortality compared to non-overt DIC. Source control remains the most important prognostic intervention.
1. Pathophysiology and Etiology
Tissue Factor Activation Cascade
DIC is initiated by widespread exposure of tissue factor (TF) to circulating factor VII, triggering the extrinsic coagulation pathway. TF is expressed on endothelial cells, monocytes, and tumor cells in response to sepsis cytokines (TNF-α, IL-1, IL-6), endothelial injury (trauma, severe burns), or tumor cell release. Massive thrombin generation overwhelms physiologic anticoagulant systems (antithrombin, protein C/S, tissue factor pathway inhibitor), producing widespread microvascular fibrin deposition. Fibrin clots in small vessels cause organ ischemia (acute kidney injury, ARDS, hepatic dysfunction, encephalopathy) and shear red blood cells passing through partially occluded vessels (microangiopathic hemolytic anemia with schistocytes).
Concurrent consumption of platelets and clotting factors produces the bleeding phenotype: thrombocytopenia, prolonged PT and aPTT, hypofibrinogenemia, and elevated D-dimer reflecting both fibrin formation and secondary fibrinolysis. The balance between thrombosis and bleeding determines clinical phenotype: acute fulminant DIC (sepsis, trauma, obstetric) typically presents with bleeding and end-organ failure; chronic compensated DIC (malignancy, aortic aneurysm, intrauterine fetal demise) presents with thrombosis and abnormal labs without overt bleeding. Most patients have features of both simultaneously.
Underlying Causes by Frequency
| Category | Specific Triggers | Phenotype |
|---|---|---|
| Sepsis (30–50%) | Gram-negative bacteremia (E. coli, Klebsiella), gram-positive sepsis, fungal sepsis, severe COVID-19 | Mixed (bleeding + thrombosis); high mortality |
| Malignancy (20–30%) | Acute promyelocytic leukemia (APL), pancreatic adenocarcinoma, prostate, lung, gastric, ovarian, breast | Chronic compensated; thrombotic in solid tumors; severe hemorrhagic in APL |
| Trauma | Severe trauma with massive transfusion, traumatic brain injury, burns >30% TBSA, crush injury | Hemorrhagic; trauma-induced coagulopathy (TIC) overlap |
| Obstetric (5–10%) | Placental abruption, amniotic fluid embolism, retained dead fetus, severe preeclampsia/HELLP, postpartum hemorrhage | Acute hemorrhagic; rapid onset and rapid resolution post-delivery |
| Vascular | Large aortic aneurysm, giant hemangioma (Kasabach-Merritt), aortic dissection | Chronic compensated; localized consumption |
| Toxic/envenomation | Snake bite (especially viperids), severe acute pancreatitis, ABO-incompatible transfusion, heatstroke | Acute mixed |
| Acute liver failure | Fulminant hepatic failure with reduced antithrombin and protein C synthesis | Mixed; overlap with hepatic coagulopathy |
2. Clinical Presentation and ISTH Diagnostic Criteria
Hemorrhagic vs Thrombotic Phenotypes
Hemorrhagic DIC (sepsis, obstetric, trauma): bleeding from venipuncture sites, IV catheter sites, surgical wounds, mucous membranes (gingival, GI, urinary tract), petechiae and purpura, hematuria. Severe cases progress to massive hemorrhage. Concurrent organ dysfunction from microthrombi causes acute kidney injury, ARDS, and encephalopathy. Schistocytes on peripheral smear, mild-moderate hemolysis.
Thrombotic DIC (chronic malignancy, aortic aneurysm, purpura fulminans): venous thromboembolism, peripheral arterial thrombosis (digital gangrene), purpura fulminans (extensive skin necrosis from microvascular thrombosis—classic in meningococcal sepsis and protein C deficiency), and end-organ ischemia without overt bleeding. Trousseau syndrome (migratory superficial thrombophlebitis) is a chronic compensated DIC variant in occult malignancy. Most patients have both phenotypic features simultaneously, with one predominating.
ISTH Overt DIC Score
| Parameter | 0 points | 1 | 2 | 3 |
|---|---|---|---|---|
| Platelet count (×10⁹/L) | >100 | 50–100 | <50 | — |
| Elevated fibrin marker (D-dimer, FDP, fibrin monomer) | None | — | Moderate increase | Strong increase |
| Prolonged PT (seconds above upper limit) | <3 | 3–6 | >6 | — |
| Fibrinogen (mg/dL) | >100 | <100 | — | — |
| Total Score | Interpretation | Action |
|---|---|---|
| <5 | Non-overt DIC (suggestive but not diagnostic) | Repeat scoring daily; treat underlying cause; consider non-overt DIC sub-score |
| ≥5 | Overt DIC (compatible with consumptive coagulopathy) | Aggressive treatment of underlying cause; component therapy if bleeding; daily score monitoring |
ISTH Score Application Caveat
The ISTH score should only be applied in patients with an underlying disorder known to cause DIC—do not apply to patients without a clinical context (e.g., isolated thrombocytopenia in an otherwise stable patient should not be scored as DIC). Trends matter more than absolute values: rapidly worsening scores indicate progressive coagulopathy and warrant escalation. The score does not differentiate hemorrhagic vs thrombotic phenotype—clinical assessment must guide management direction.
3. Differential Diagnosis: DIC vs Other Coagulopathies
| Feature | DIC | Severe Liver Disease | Vitamin K Deficiency | TTP/HUS |
|---|---|---|---|---|
| Platelet count | ↓ (consumption) | ↓ (sequestration in cirrhosis) | Normal | ↓ (thrombosis) |
| PT/INR | ↑ | ↑ | ↑↑ (factor VII shortest half-life) | Normal |
| aPTT | ↑ | ↑ | ↑ (later) | Normal |
| Fibrinogen | ↓ (acute) / Normal-↑ (acute phase) | ↓ (synthesis failure) | Normal | Normal |
| D-dimer | ↑↑↑ (markedly elevated) | Normal-mild ↑ | Normal | Mildly ↑ |
| Factor VIII | Normal-↑ (endothelial release) | ↓ (synthesis failure) | Normal | Normal-↑ |
| Schistocytes on smear | + to ++ | Rare | None | +++ |
| ADAMTS13 activity | Normal or mildly low | Normal | Normal | <10% |
| Treatment focus | Underlying cause + components | Underlying liver disease | Vitamin K + plasma if bleeding | Plasma exchange |
Distinguishing DIC from Liver Disease Coagulopathy
Both produce thrombocytopenia and prolonged INR/aPTT, but the most reliable discriminators are: factor VIII levels (normal/elevated in DIC due to endothelial release; reduced in liver disease due to synthesis failure), D-dimer (markedly elevated in DIC; mild in liver disease), and clinical context (acute trigger like sepsis vs chronic liver dysfunction with portal hypertension). Patients with cirrhosis and superimposed sepsis frequently have BOTH conditions, complicating both interpretation and management.
4. Treatment: Source Control and Component Therapy
Underlying Cause Management — The Critical Intervention
The most important intervention in DIC is aggressive treatment of the underlying disorder. Sepsis-associated DIC: empiric broad-spectrum antibiotics within 1 hour (sepsis bundle), source control (drainage of abscess, removal of infected hardware), hemodynamic resuscitation, vasopressors as needed. Obstetric DIC: delivery of fetus and placenta is curative for placental abruption, retained dead fetus syndrome, and preeclampsia/HELLP-associated DIC—coagulopathy resolves rapidly post-delivery. APL-associated DIC: immediate ATRA 45 mg/m²/day PO on suspicion (do not wait for cytogenetic confirmation), plus arsenic trioxide. Trauma DIC: damage control surgery, hemostatic resuscitation with balanced 1:1:1 RBC:plasma:platelets, tranexamic acid 1 g IV over 10 min then 1 g over 8 hours if within 3 hours of injury (CRASH-2). Snake envenomation: species-specific antivenom.
Component Therapy Thresholds
| Component | Indication | Dose | Goal |
|---|---|---|---|
| Platelets | <50,000/µL with active bleeding or before invasive procedure; <20,000/µL without bleeding (prophylactic) | 1 unit per 10 kg (typical adult: 1 apheresis unit ≈ 6 random units) | Maintain >50,000/µL with bleeding; >100,000/µL with CNS hemorrhage or surgery |
| Fresh frozen plasma (FFP) | INR >1.5 OR aPTT >1.5× normal WITH active bleeding or planned procedure | 10–15 mL/kg IV (adult: 4–6 units typical) | Reduce INR <1.5; correct factor deficiencies |
| Cryoprecipitate | Fibrinogen <150 mg/dL with bleeding (or <200 mg/dL in obstetric DIC) | 1 unit per 5–10 kg IV (adult: 10 units typical) | Fibrinogen >150 mg/dL (obstetric: >200) |
| Fibrinogen concentrate | Same as cryoprecipitate; preferred when available (lower volume, faster correction) | 25–50 mg/kg IV (adult: 2–4 g) | Same as cryoprecipitate |
| 4-factor PCC (Kcentra) | Reserved for warfarin reversal in DIC; insufficient evidence as routine DIC therapy | 25–50 units/kg IV based on INR | Rapid factor replacement |
Avoid Prophylactic Component Transfusion
Transfuse blood components ONLY in actively bleeding patients or before planned invasive procedures—do not chase abnormal labs in stable, non-bleeding DIC patients. Prophylactic component therapy in stable DIC has not been shown to reduce mortality and may worsen volume overload, transfusion reactions, and immunomodulation. The exception is prophylactic platelets <20,000/µL to prevent spontaneous CNS hemorrhage in chemotherapy-induced thrombocytopenia and high-risk DIC.
5. Anticoagulation, Adjuncts, and Special Scenarios
Anticoagulation — Phenotype-Driven
Therapeutic anticoagulation in DIC is reserved for the thrombotic phenotype: chronic compensated DIC from solid malignancy (especially Trousseau syndrome), large-vessel thrombosis (deep vein thrombosis, pulmonary embolism), purpura fulminans, and giant hemangioma (Kasabach-Merritt). Heparin (UFH or LMWH) reduces ongoing thrombin generation and may stabilize the coagulopathy. Use low-dose continuous UFH ~10 units/kg/hr infusion without a bolus, or low-dose enoxaparin 1 mg/kg SC q12h. Monitor anti-Xa levels (target 0.3-0.7) rather than aPTT in DIC because baseline aPTT is already prolonged.
Therapeutic anticoagulation is contraindicated in acute hemorrhagic DIC (sepsis, obstetric, trauma) where it worsens bleeding without proven survival benefit. Prophylactic-dose VTE prevention (LMWH enoxaparin 40 mg SC daily or UFH 5,000 units SC q8h) should generally continue in critically ill DIC patients without active bleeding because VTE risk remains elevated. Decision requires individualized risk-benefit assessment with hematology consultation.
Adjunctive and Investigational Therapies
| Therapy | Indication | Evidence |
|---|---|---|
| Tranexamic acid (TXA) | Trauma DIC within 3 hours; obstetric hemorrhage (WOMAN trial) | CRASH-2: mortality reduction in trauma; WOMAN: maternal mortality reduction in PPH |
| Antithrombin concentrate | Severe sepsis-associated DIC with antithrombin <70% | Limited; routine use not recommended |
| Recombinant thrombomodulin (Recomodulin) | Sepsis-associated DIC (Japan-approved) | SCARLET trial: no overall survival benefit; subgroup signals in coagulopathic patients |
| Activated protein C (drotrecogin alfa) | Withdrawn from market (PROWESS-SHOCK negative) | No longer available |
| Recombinant factor VIIa (NovoSeven) | Refractory life-threatening hemorrhage as last resort | Limited evidence; thromboembolic risk; off-label outside hemophilia |
When to Refer / Hospitalize
Hematology consultation: all suspected DIC cases require hematology involvement, especially for thrombotic phenotype, refractory coagulopathy, or atypical features. ICU admission: DIC by definition is critically ill—admit to ICU for hemodynamic monitoring, source control, and component therapy. Multidisciplinary care: trauma (surgery + transfusion medicine), obstetric (OB + neonatology), oncology (heme-onc + surgical onc), infectious disease (sepsis source control). Massive transfusion protocol activation: hemorrhagic DIC with ongoing bleeding meeting massive transfusion criteria (≥10 units RBC in 24h or ≥4 units in 1 hour) requires balanced 1:1:1 component delivery.
Special Scenarios
Acute promyelocytic leukemia (APL)-DIC: ATRA 45 mg/m²/day PO divided BID immediately on morphologic suspicion; do not wait for cytogenetic confirmation. APL DIC produces severe hemorrhagic phenotype with intracranial hemorrhage being leading cause of early death. ATRA differentiation rapidly resolves coagulopathy within days. Add arsenic trioxide for low-risk APL or chemotherapy combinations for high-risk.
Obstetric DIC: placental abruption, amniotic fluid embolism, retained dead fetus syndrome, and severe preeclampsia/HELLP cause acute fulminant DIC. Delivery is the most important intervention—coagulopathy resolves within 24-48 hours. Maintain fibrinogen >200 mg/dL (higher than non-pregnant threshold). Tranexamic acid 1 g IV is recommended in postpartum hemorrhage per WOMAN trial.
Snake envenomation: viperid envenomation causes consumptive coagulopathy via venom-induced fibrinogenolysis and prothrombin activation. Species-specific antivenom is curative; component therapy is bridging. Avoid heparin.
Practice Insights: Source Control Beats Factor Replacement, Symptom-Driven Transfusion, Avoid TXA
ISTH Score Anchors Diagnosis
in experienced hands, the ISTH (International Society on Thrombosis and Haemostasis) DIC score is the diagnostic anchor: platelet count (>100 = 0, 50-100 = 1, <50 = 2), elevated FDP/D-dimer (no rise = 0, moderate rise = 2, strong rise = 3), PT prolongation (<3 sec = 0, 3-6 sec = 1, >6 sec = 2), fibrinogen (>100 mg/dL = 0, <100 = 1). Score ≥5 with underlying condition known to cause DIC = overt DIC. Score <5 = non-overt or developing DIC, monitor closely. Add clinical context: bleeding (skin/mucosal/surgical sites/IV lines), thrombosis (peripheral cyanosis, microvascular dysfunction), or both. Note that fibrinogen is an acute-phase reactant so may be falsely normal early; trend matters more than absolute value.
Source Control Is Everything
The single most important intervention is source control — DIC will continue unabated until the trigger is addressed. Sepsis: rapid empiric broad-spectrum antibiotics + source identification + drainage of any abscess + lactate-guided resuscitation. Obstetric emergencies (amniotic fluid embolism, abruption, retained products): urgent OB intervention — uterine evacuation, possible emergency hysterectomy for severe atonic bleeding. Malignancy-driven DIC (APL, mucinous adenocarcinoma): treat the cancer; APL specifically requires ATRA + arsenic trioxide which dramatically reverses the DIC. Trauma DIC: surgical hemostasis + warming + balanced massive transfusion. Snake envenomation: appropriate antivenom. Until source is controlled, transfused components are consumed and lost.
Symptom-Driven Transfusion, Not Lab-Driven
Component therapy in DIC is symptom-driven, not lab-driven — transfuse only if patient is actively bleeding or before an invasive procedure. The triggers: Platelets <50K with bleeding or pre-procedure; <20K prophylactic in non-bleeding patient (or <10K if absolutely stable). FFP if INR >1.5 with active bleeding (15-20 mL/kg, expect 30% factor activity rise) or before procedure with INR >1.5. Cryoprecipitate if fibrinogen <100-150 mg/dL with bleeding (1 unit per 10 kg raises fibrinogen ~70 mg/dL). PCC 4-factor (Kcentra) is an alternative when rapid factor correction needed and FFP not feasible. Transfusing to normalize labs in non-bleeding DIC patients wastes blood products, exposes to TRALI/TACO risk, and can paradoxically feed the consumption cycle.
Avoid TXA in Most DIC — and Heparin Only Thrombotic Phenotype
The two most consequential pharmacologic decisions in DIC: tranexamic acid (TXA) is generally CONTRAINDICATED in DIC because antifibrinolytics worsen the microvascular thrombosis component — exceptions are specific scenarios (APL with low fibrinolysis after ATRA initiation, severe hemorrhage in trauma DIC where benefits may outweigh thrombosis risk per CRASH-2 protocol within 3 hours of injury). Heparin (typically unfractionated 5-10 U/kg/hr without bolus) is reserved for chronic compensated DIC with predominant thrombotic phenotype — classically Trousseau syndrome (cancer-associated DIC with thrombotic manifestations), purpura fulminans, or large-vessel thrombosis. Acute hemorrhagic DIC generally does NOT benefit from heparin and may worsen bleeding. Activated protein C (drotrecogin alfa) was withdrawn from market (PROWESS-SHOCK trial failure).
Illustrative Scenario
A patient in their twenties presented postpartum 6 hours after delivery with progressive vaginal bleeding, uterine atony despite uterotonics, oozing from IV sites, and petechiae. Labs: Hb 7.2, platelets 38K, fibrinogen 95 mg/dL, PT 22 sec (control 12), D-dimer markedly elevated. ISTH score: platelets 2 + D-dimer 3 + PT 2 + fibrinogen 1 = 8, overt DIC. Initial treatment focused on transfusion (platelets, FFP, cryoprecipitate) but bleeding continued. On consultation, bedside ultrasound revealed retained placental fragments — the unaddressed source. Urgent uterine curettage was performed; concurrent administration of massive transfusion protocol (1:1:1 ratio PRBC:FFP:platelets), cryoprecipitate to maintain fibrinogen >150 mg/dL, and tranexamic acid (per OB hemorrhage protocol — exception to general DIC avoidance). Within 4 hours of source control + balanced transfusion, bleeding ceased, platelets and fibrinogen began rising, and ISTH score normalized over 48 hours. Patient survived without need for hysterectomy.
Practice Pattern Refinements vs Standard Algorithm
- ISTH score with clinical context, not labs alone. Platelets + D-dimer + PT + fibrinogen + underlying condition. Score ≥5 = overt DIC. Watch for fibrinogen falsely normal early (acute-phase reactant); trend matters more.
- Source control is the primary intervention. Sepsis abx + drainage. OB urgent evacuation. APL: ATRA + ATO. Trauma: surgical hemostasis + balanced massive transfusion. Snake: antivenom. Until source addressed, transfusion is wasted product.
- Symptom-driven (not lab-driven) transfusion. Plt <50K + bleeding, FFP if INR >1.5 + bleeding, cryo if fibrinogen <100-150 + bleeding. Prophylactic Plt <20K. Do NOT transfuse to normalize labs in non-bleeding patients.
- Avoid TXA in most DIC; heparin only thrombotic phenotype. TXA worsens microvascular thrombosis — exceptions are APL post-ATRA and trauma per CRASH-2. Heparin (UFH 5-10 U/kg/hr no bolus) for chronic compensated DIC with thrombotic phenotype (Trousseau, purpura fulminans).
6. Pearls, Pitfalls, and Clinical Wisdom
Pearl 1: DIC Is Always Secondary—Find and Treat the Cause
DIC is never primary; it is always a consequence of another disorder. The most important therapeutic action is identifying and aggressively treating the underlying trigger: source control for sepsis, delivery for obstetric DIC, ATRA for APL, surgical control for trauma. Component therapy alone without addressing the root cause does not improve outcomes. Spending energy on transfusion thresholds while missing the source is a common pitfall.
Pitfall 1: Treating Lab Values Instead of Bleeding
Prophylactically transfusing components to "normalize" abnormal coagulation labs in stable, non-bleeding DIC patients does not improve outcomes and risks volume overload, transfusion reactions, TRALI, and immunomodulation. Reserve component therapy for active bleeding or planned invasive procedures. The exception is prophylactic platelets <20,000/µL to prevent spontaneous intracranial hemorrhage.
Pearl 2: D-dimer Distinguishes DIC from Liver Coagulopathy
Both DIC and severe liver disease produce thrombocytopenia and prolonged INR/aPTT, but D-dimer is markedly elevated in DIC (often >5,000 ng/mL FEU) and only mildly elevated in liver disease. Factor VIII is normal/elevated in DIC (endothelial release) and reduced in liver disease (hepatic synthesis failure). Combined with clinical context (acute trigger vs chronic liver dysfunction), these markers reliably differentiate.
Pitfall 2: Heparin in Hemorrhagic DIC
Therapeutic heparin in acute hemorrhagic DIC (sepsis, obstetric, trauma) worsens bleeding without proven survival benefit and is contraindicated outside specific scenarios. Reserve therapeutic anticoagulation for chronic compensated DIC with thrombotic phenotype—Trousseau syndrome, large-vessel VTE, purpura fulminans, Kasabach-Merritt. Prophylactic VTE dose is acceptable in stable critically ill DIC patients without active bleeding.
Pearl 3: APL-Associated DIC Is a True Emergency
Acute promyelocytic leukemia (APL) produces severe hemorrhagic DIC; intracranial hemorrhage is the leading cause of early death (within 30 days of diagnosis). Start ATRA 45 mg/m²/day immediately upon morphologic suspicion of APL—do NOT wait for cytogenetic PML-RARα confirmation. ATRA resolves coagulopathy within days through differentiation of malignant promyelocytes. Aggressive component therapy with platelets >30k, fibrinogen >150 mg/dL, INR <1.5 reduces hemorrhagic mortality.
Pitfall 3: Single Snapshot ISTH Score Without Trend
A single ISTH score <5 does not exclude DIC if trajectory is unfavorable. Repeat scoring every 24 hours in any patient with DIC trigger and abnormal coagulation; rapidly worsening scores indicate progressive coagulopathy and demand escalation. Conversely, a falling score reassures that source control is working. The ISTH non-overt DIC sub-score adds dynamic markers (changes in platelets, PT, fibrin marker, fibrinogen) for early detection.
Frequently Asked Questions
The ISTH overt DIC score uses 4 routine laboratory parameters: platelet count (>100k=0, 50-100k=1, <50k=2), elevated fibrin marker (D-dimer or FDP) (no=0, moderate=2, strong=3), prolonged PT (<3s=0, 3-6s=1, >6s=2), and fibrinogen (>100=0, <100=1). Total ≥5 confirms overt DIC. Score should only be applied if an underlying disorder known to cause DIC is present. Repeat daily to track progression or improvement.
Transfuse platelets if count <50,000/µL with active bleeding, planned invasive procedure, or postpartum/postoperative; <20,000/µL without bleeding. FFP 10-15 mL/kg if INR >1.5 or aPTT >1.5× normal with active bleeding. Cryoprecipitate or fibrinogen concentrate if fibrinogen <150 mg/dL with bleeding (or <200 mg/dL in obstetric DIC). Avoid prophylactic transfusion in non-bleeding stable patients—correct labs only when bleeding or before procedures.
Therapeutic-dose anticoagulation (heparin or LMWH) is reserved for the thrombotic phenotype of DIC—predominantly chronic DIC from solid malignancy, large-vessel thrombosis, or purpura fulminans. In acute hemorrhagic DIC (sepsis, obstetric, trauma), therapeutic anticoagulation worsens bleeding. Prophylactic-dose VTE prophylaxis (LMWH or UFH) should continue in critically ill DIC patients without active bleeding. Decision requires hematology input and individualized risk-benefit assessment.
Both produce prolonged INR/aPTT, low platelets, and bleeding tendency. Distinguishing features: factor VIII levels (preserved or elevated in DIC because endothelial-derived; low in liver disease), D-dimer (markedly elevated in DIC; mildly elevated in liver disease), platelet count trajectory (rapidly falling in acute DIC; chronic stable cytopenia in cirrhosis), and underlying clinical context (sepsis/malignancy/obstetric trigger for DIC; portal hypertension/jaundice for liver disease). Both may coexist.
DIC mortality depends on underlying cause and severity. Sepsis-associated DIC carries 40-60% mortality; trauma-associated DIC 30-50%; obstetric DIC <10% with prompt management; malignancy-associated chronic DIC has variable outcomes tied to cancer trajectory. ISTH score ≥5 doubles mortality compared to non-overt DIC. Treatment of underlying cause is the most important prognostic intervention; supportive component therapy alone without source control rarely improves outcomes.
- Smoldering Multiple Myeloma: Risk Stratification, Surveillance, and When to Treat
- Iron Deficiency Anemia: Evaluation, Etiology Workup, and Evidence-Based Repletion
- Venous Thromboembolism — DVT and Pulmonary Embolism Management
- Hereditary Spherocytosis: Diagnosis, Severity, and Splenectomy Decisions
- Sickle Cell Vaso-Occlusive Crisis: ED Management and Pain Control
- Multiple Myeloma: Diagnosis, R-ISS Staging, and Induction/Transplant Pathways